Monoclonal Antibodies For COVID Suffer Access Problems Due To Limited Infusion Reimbursement
Unused supply for the Lilly and Regeneron therapies has policymakers considering Medicare payment changes for providers managing outpatient infusion, but those may require legislation. National Academies of Sciences, Engineering and Medicine committee considers the ‘paradox of unused supply with a relatively scarce product’ and tries to dissect the challenges that may be contributing to the unexpected lack of take-up for the mABs.
You may also be interested in...
Regeneron and Eli Lilly have seen limited uptake for their COVID treatments; CMS payment increase addresses concerns that inadequate reimbursement has hampered use of the monoclonal antibody drugs.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
Lilly’s fourth-quarter results included windfalls, not just from the pandemic but from seasonal wholesaler buying patterns that were intensified by the pandemic and raise a high bar for subsequent quarters.